News Articles

Galderma to Present New Clinical Data and High Patient Satisfaction Across Their Portfolio of Dermal Fillers, Collagen... LAUSANNE, Switzerland -Monday 28 March 2022  

Alluzience® (abobotulinumtoxinA, ABO) improves glabellar (frown) lines with high patient satisfaction Positive new data on the efficacy and safety of the new formulation of Sculptra® (poly-L-lactic acid, PLLA) Strong data from two studies showing the efficacy and safety...

Galderma to Highlight Latest Science and Innovation Across Its Product Portfolio at the 2022 AAD Annual Meeting -Friday 25 March 2022  

(BUSINESS WIRE) -- Galderma, the leading company solely dedicated to advancing the future of dermatology, announced it will be attending the 2022 American Academy of Dermatology Annual Meeting to showcase its latest approved and investigational product updates. This includes clinical data...

Taro to Acquire Alchemee From Galderma -Wednesday 23 February 2022  

(BUSINESS WIRE) -- Galderma and Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro”) announced today they have signed a definitive agreement for Taro to acquire Alchemee, formerly The Proactiv Company (TPC), from Galderma. The agreement between Galderma and Taro includes Alchemee’s...

Karen L. Ling joins Galderma’s Advisory Committee -Friday 18 February 2022  

(BUSINESS WIRE)-- Galderma, the world’s largest independent dermatology company, announced today that Karen L. Ling will join its Advisory Committee, effective March 1, 2022. Karen Ling has a tremendous track record in executive roles at AIG, Allergan, Merck and Wyeth, guiding compensation,...

Galderma Successfully Completes Acquisition of ALASTIN Skincare® -Wednesday 5 January 2022  

(BUSINESS WIRE) -- Galderma, the world’s largest independent dermatology company, announced today that it has received antitrust clearance from the U.S. authorities and has completed the acquisition of ALASTIN Skincare®, Inc. (“ALASTIN”), a specialty aesthetics company dedicated to...

Maria Teresa Hilado to Join Galderma’s Advisory Committee -Tuesday 7 December 2021  

(BUSINESS WIRE)-- Galderma, the world’s largest independent dermatology company, announced today that Maria Teresa “Tessa” Hilado will join its Advisory Committee, effective January 1, 2022. Ms. Hilado currently serves on the board of directors at Campbell Soup Company, Zimmer Biomet...

Galderma Announces New Data Demonstrating the Positive Anti-inflammatory Effect and Mode of Action of Nemolizumab in... -Monday 6 December 2021  

(BUSINESS WIRE)-- Galderma today announced that the Journal of Allergy and Clinical Immunology has published gene expression data that demonstrate the positive anti-inflammatory effect and mode of action of nemolizumab in patients with moderate to severe Prurigo Nodularis (PN), confirming the...

​​​​​​​​​​​​​​Galderma to Acquire Award-winning ALASTIN... -Monday 29 November 2021  

(BUSINESS WIRE)-- Galderma, the world’s largest independent dermatology company, announced that it has signed a definitive agreement to acquire ALASTIN Skincare®, Inc. (“ALASTIN”), a specialty aesthetics company dedicated to developing innovative and clinically-tested physician-dispensed...

RESTYLANE®, the Original Stabilized Hyaluronic Acid Filler, Celebrates 25 Years of Unmatched Achievement ... -Thursday 30 September 2021  

(BUSINESS WIRE) -- Galderma, the world’s largest independent dermatology company, today marks the 25th anniversary of RESTYLANE®. The original non-animal stabilized hyaluronic acid filler restores, enhances and refreshes the youthful-looking appearance of the skin. Since launching in Europe...

Galderma Presents New Nemolizumab Data at EADV Reinforcing Rapid Onset of Action and Consistent Relief of Symptoms for... -Wednesday 29 September 2021  

(BUSINESS WIRE) -- Galderma today announced the presentation of new phase 2 data supporting the efficacy of its investigational monoclonal antibody, nemolizumab, at the virtual 30th EADV congress, taking place between 28 September and 2 October 2021. Results from two key trials of...

Galderma Announces Exclusive Agreement With Sofregen to Develop the Next Generation of Biostimulator Fillers Using... -Thursday 23 September 2021  

(BUSINESS WIRE) -- Galderma, the world’s largest independent dermatology company, and Sofregen Medical, Inc., a medical device company pioneering the use of silk protein for tissue building and regeneration, announced today they have signed a co-development and option-to-acquire...

Galderma to Present New Data From Leading Aesthetics Portfolio and Launch* RESTYLANE® EYELIGHT™ at... -Thursday 9 September 2021  

Data for SCULPTRA® to support new administration method licensed in Europe that is fast and convenient - ALLUZIENCE® data to reaffirm effectiveness and safety of first ready-to-use liquid formulation licensed in Europe - Galderma to host sponsored symposium to discuss initial assessment...

Sol-Gel Technologies and Galderma Announce Exclusive Licenses for the Commercialization of EPSOLAY® and TWYNEO®... -Monday 28 June 2021  

- Upfront and approval payments of up to $15 million - Tiered royalties ranging from mid- to high-teen percentage of net sales - Sol-Gel option to regain commercialization rights 5 years following first commercialization (BUSINESS WIRE)-- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a...

Galderma Announces Publication of Phase 2b Trial Results Demonstrating the Rapid and Long-lasting Benefits of... -Thursday 8 April 2021  

Atopic dermatitis is the most common type of eczema. Moderate to severe atopic dermatitis is a chronic and incurable condition, severely disrupting patients’ quality of life1 The outcome of a post-hoc analysis of the phase 2b study published in the Journal of the European Academy of...

Galderma Continues Global Growth Ambition With Sculptra® (injectable poly-L-lactic Acid) Re-launch in Europe -Thursday 4 March 2021

Updated administration protocol means Sculptra®offers the fastest reconstitution of any injectable poly-L-lactic acid (PLLA) available in Europe Updated protocol allows for faster and more convenient administration of Sculptra®with the optional addition of lidocaine to increase patient...

Galderma Announces Top-line Results from Phase 2 Clinical Dose-Escalating Study with Azzalure® /... -Tuesday 1 December 2020

(BUSINESS WIRE)-- Galderma today announced top-line results from a Phase 2 study on the impact of dose escalation on the duration of effect and the efficacy and safety of a single dose of Dysport® (abobotulinumtoxinA) for Injection (50U, 75U, 100U or 125U) versus placebo for the treatment of...

Galderma To Present Five Abstracts in Support of Novel Aesthetics Solutions and Pipeline at ASDS 2020 Annual Meeting -Saturday 10 October 2020

(BUSINESS WIRE)-- Galderma today announced the presentation of data from clinical trials of its aesthetic solutions and pipeline in five abstracts at the virtual American Society for Dermatologic Surgery (ASDS) 2020 Annual Meeting. The company also announced that it has completed patient...

Galderma Announces New England Journal of Medicine Publication from Phase 2 Study of Investigational Therapy Nemolizumab... -Thursday 20 February 2020

(BUSINESS WIRE)-- Galderma today announced that The New England Journal of Medicine (NEJM) has published full results from the Phase 2 study of its investigational therapy nemolizumab in adult patients suffering from moderate-to-severe prurigo nodularis (PN). PN is a rare, potentially...

Galderma Investigational Therapy Nemolizumab Granted FDA Breakthrough Therapy Designation for the Treatment of Patients... -Monday 9 December 2019

(BUSINESS WIRE) -- Galderma today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to the investigational therapy nemolizumab for the treatment of pruritus associated with prurigo nodularis. Prurigo nodularis is a rare, potentially...

Galderma Advances Phase 3 Clinical Study with Nemolizumab in Moderate-to-Severe Atopic Dermatitis -Thursday 10 October 2019

(BUSINESS WIRE)-- Galderma, a global leader focused on meeting the world's increasing skin health needs, announced that it has enrolled the first patients in a new Phase 3 clinical study with nemolizumab, an investigational therapy in adult patients with moderate-to-severe atopic...

Results 1-20 of 24